Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (73)	6/6/2008 1:34:28 PM
From: Biomaven	Read Replies (1) \| Respond to of 78

If the FDA doesn't accede to a request for an AC they have to state their reasons in writing and their adverse decision is subject to review up the chain of command at the FDA. I think that in a case like this (a marginal-looking safety issue) they would pretty much have to accede to the request for an AC. fda.gov Of course there is a potential cost to pissing-off the FDA by trying to have the decision overturned - but given the turnover at the FDA these days any folks you piss off probably won't be there that long anyhow. :) Maybe we can get Mark McClellan back at the FDA under the next administration given his brother just broke ranks with the current administration. Peter